The Flint, Michigan, lead-in-the-water crisis has uncovered a massive health threat that extends across America. The issue is lead, and other environmental toxins, and what those toxins are doing to our health, including triggering the onset of cancer, particularly in our children.
Scientists have long believed that high concentrations of heavy metals are a major underlying cause of blood cancers. But at present, there is no definitive scientific research that demonstrates how lead, and other heavy metals, are connected to leukemia and other blood cancers.
Cancer Recovery Foundation has taken the major step of funding a scientific study at the world-renowned M.D. Anderson Cancer Center in Houston, Texas, to find the answer to this important question. The study represents an important and overlooked step toward developing less-toxic, more-effective and less-costly treatments for blood-based cancers.
The initial research will be focused on pediatric cancer patients — half of whom are newly diagnosed with acute lymphoblastic leukemia and half who are newly diagnosed with acute myeloid leukemia.
This ground-breaking research is headed by Maro Ohanian, D.O., Assistant Professor at the University of Texas M.D. Anderson Cancer Center. Dr. Ohanian is widely recognized as a pioneer in understanding the link between environmental toxins and leukemia.
This type of research seldom wins support in the competitive and largely pharmaceutical-based federal agency grant making environment. Metal accumulation and the need to eliminate toxic metals in the cancer treatment process represents a significant gap in current cancer treatment options. Moreover, answering the question of how accumulation of metals from food and water contribute to an individual’s risk for cancer may well lead to actual cancer prevention.
Cancer Recovery Foundation believes that an understanding of the impact of metal concentrations in leukemia patients could quickly lead to new therapeutic approaches. This would include incorporation of metal-targeted metal-binding agents during the course of leukemia treatment. It is hoped this research will lead to new and more effective treatments for leukemia, as well as other cancers, thus saving thousands of lives annually.